News

Today, scientists increasingly recognise severe periodontitis as more than a disease of the mouth. It’s a chronic inflammatory condition driven by bacterial infection that may influence health throughout the body. We sat down with Denteric’s Chief Operating Officer, Larisa Chisholm, to talk about the challenge they are working to solve.

The Wall Street Journal explores the link between oral and systemic health and how periodontitis may increase systemic inflammation and affect longevity, heart diseases and dementia.

Denteric’s therapy is highlighted among innovative approaches linking oral and systemic health.

Denteric today announced the commencement of participant recruitment for a Phase I clinical study of its first-in-class therapy for Alzheimer’s disease.

Denteric Announces FDA IND Clearance for GPV381, a First-in-Class Therapeutic Vaccine Targeting Gingipain-Driven Inflammation in Periodontitis 

Denteric’s executive team CEO Sean McLoughlin, COO Larisa Chisholm and CSO Paul Cockle will be at the World Vaccine Congress Washington from 30 March – 2^nd April We look forward to connecting with those interested in learning more about GPV381.

Denteric’s CEO Sean McLoughlin looks forward to connecting at J.P.M. 2026

Denteric awarded $2.5M CUREator+ Dementia and Cognitive Decline funding to support a phase I safety study in early-stage Alzheimer’s disease (AD) patients using Denteric’s GPV381 therapy.

Denteric is pleased to advise that it has completed recruitment and dosing of 3 cohorts in its Phase I GPV381 clinical trial.

Denteric is pleased to announce that its first subjects have been dosed today in its first in human safety study of GPV381, a therapy designed to treat severe periodontal disease.  The phase 1 study will assess safety and tolerability of the therapy in healthy subjects and is being conducted at Nucleus Networks Phase I Unit in Melbourne.

Round one provided support to Denteric, an early-stage biotech developing therapies targeting  Porphyromonas gingivalis (Pg) related diseases – initially focused on severe periodontal disease.

Recent success with Pfizer and Moderna vaccines to Covid-19 has proven efficacy of mRNA vaccines for viruses, but little is known about using mRNA against bacterial pathogens, which are equally abundant.

Denteric co-founder Professor Reynolds has been recognised for his outstanding achievement in translating scientific discoveries into globally successful products that prevent and treat oral disease.

CSL-backed biotech company Denteric has closed a $14 million funding round, enabling it to develop a vaccine for a gum disease that affects one in three adults globally, with a human clinical trial expected within three years.

A vaccine for periodontal gum disease, which affects a third of all adults globally, is in development following a $14 million investment into newly-formed biotech company Denteric Pty Ltd.